# Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure.

> **NCT01122979** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 72 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** INSULIN GLARGINE
- **DRUG:** NPH insulin (insulin isophane)
- **DRUG:** INSULIN GLULISINE
- **DRUG:** Regular insulin

## Key facts

- **NCT ID:** NCT01122979
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2013-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01122979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01122979, "Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01122979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*